nimotuzumab + tislelizumab

Nimotuzumab + tislelizumab is a combination therapy consisting of two monoclonal antibodies used in the treatment of certain cancers. Nimotuzumab is an epidermal growth factor receptor (EGFR) inhibitor, while tislelizumab is a programmed cell death protein 1 (PD-1) inhibitor. This combination leverages both targeted therapy and immunotherapy mechanisms to inhibit tumor growth and enhance anti-tumor immune responses. Clinical studies have shown that this regimen offers promising efficacy with low toxicity for patients with recurrent or metastatic oral squamous cell carcinoma (OSCC), particularly those with poor performance status who may not tolerate conventional chemotherapy[1][2]. The combination has also been investigated in other solid tumors such as cervical cancer[6].